Metabolic memory: Mechanisms and implications for diabetic retinopathy

Diabetes Research and Clinical Practice

Volumn 96, Issue 3, 2012, Pages 286-293

  Zhang, Liwei ^a   Chen, Baihua ^a   Tang, Luosheng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Diabetic retinopathy; Mechanism; Metabolic memory; Molecular therapeutics

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GLICLAZIDE; HEMOGLOBIN A1C; INSULIN; MANGANESE SUPEROXIDE DISMUTASE; METFORMIN; REACTIVE OXYGEN METABOLITE; SULFONYLUREA DERIVATIVE; TELMISARTAN;

BLINDNESS; DIABETIC RETINOPATHY; DNA METHYLATION; EPIGENETICS; GLYCEMIC CONTROL; HISTONE ACETYLATION; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; METABOLIC MEMORY; METABOLISM; MITOCHONDRIAL ENERGY TRANSFER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; REVIEW; VISUAL IMPAIRMENT;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; OXIDATIVE STRESS;

EID: 84862158933     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.12.006     Document Type: Review

References (60)

1. Fong D.S., Aiello L., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., et al. Retinopathy in diabetes. Diabetes Care 2004, 27(Suppl. 1):84-87.
2. Wang F.H., Liang Y.B., Zhang F., Wang J.J., Wei W.B., Tao Q.S., et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology 2009, 116:461-467.
3. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003, 290(October (16)):2159-2167. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.
4. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
5. Drzewoski J., Kasznicki J., Trojanowski Z. The role of metabolic memory in the natural history of diabetes mellitus. Pol Arch Med Wewn 2009, 119(July-August):493-500.
6. Ceriello A. Hypothesis: the metabolic memory, the new challenge of diabetes. Diabetes Res Clin Pract 2009, 86(December (Suppl. 1)):S2-S6.
7. Ceriello A., Ihnat M.A., Thorpe J.E. Clinical review 2: the metabolic memory: is more than just tight glucose control necessary to prevent diabetic complications. J Clin Endocrinol Metab 2009, 94:410-415.
8. Engerman R.L., Kern T.S. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987, 36:808-812.
9. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(September (14)):977-986.
10. Epidemiology of Diabetes Interventions and Complications (EDIC) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999, 22(January (1)):99-111.
11. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000, 342(February (6)):381-389.
12. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287(May (19)):2563-2569.
13. White N.H., Sun W., Cleary P.A., Danis R.P., Davis M.D., Hainsworth D.P., et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the diabetes control and complications trial. Arch Ophthalmol 2008, 126:1707-1715.
14. American Diabetes Association Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 1998, 21(December (12)):2180-2184.
15. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R. Neil HA.10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
16. Motiejūnaite R., Kazlauskas A. Pericytes and ocular diseases. Exp Eye Res 2008, 86:171-177.
17. Hammes H.P., Klinzing I., Wiegand S., Bretzel R.G., Cohen A.M., Federlin K. Islet transplantation inhibits diabetic retinopathy in the sucrose-fed diabetic Cohen rat. Invest Ophthalmol Vis Sci 1993, 34:2092-2096.
18. Engerman R.L., Kern T.S. Retinopathy in galactosemic dogs continues to progress after cessation of galactosemia. Arch Ophthalmol 1995, 113:355-358.
19. Kador P.F., Takahashi Y., Akagi Y., Neuenschwander H., Greentree W., Lackner P., et al. Effect of galactose diet removal on the progression of retinal vessel changes in galactose-fed dogs. Invest Ophthalmol Vis Sci 2002, 43:1916-1921.
20. Cusick M., Chew E.Y., Ferris F., Cox T.A., Chan C.C., Kador P.F. Effects of aldose reductase inhibitors and galactose withdrawal on fluorescein angiographic lesions in galactose-fed dogs. Arch Ophthalmol 2003, 121:1745-1751.
21. Kowluru R.A., Chan P.S. Metabolic memory in diabetes - from in vitro oddity to in vivo problem: role of apoptosis. Brain Res Bull 2010, 81:297-302.
22. Kowluru R.A., Kanwar M., Kennedy A. Metabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries. Exp Diabetes Res 2007, 2007:21976.
23. Kanwar M., Kowluru R.A. Role of glyceraldehyde 3-phosphate dehydrogenase in the development and progression of diabetic retinopathy. Diabetes 2009, 58:227-234.
24. Kowluru R.A., Chan P.S. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007, 2007:43603.
25. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
26. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070.
27. Ceriello A., Esposito K., Ihnat M., Thorpe J., Giugliano D. Long-term glycemic control influences the long-lasting effect of hyperglycemia on endothelial function in type 1 diabetes. J Clin Endocrinol Metab 2009, 94(August):2751-2756. [Epub 2009 Jun 2].
28. Ceriello A., Esposito K., Ihnat M., Thorpe J., Giugliano D. Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in Type 1 diabetic patients with different characteristics. Diabet Med 2010, 27(August):911-917.
29. Kowluru R.A. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 2003, 52:818-823.
30. Kowluru R.A., Koppolu P. Termination of experimental galactosemia in rats, and progression of retinal metabolic abnormalities. Invest Ophthalmol Vis Sci 2002, 43:3287-3291.
31. Ihnat M.A., Thorpe J.E., Kamat C.D., Szabó C., Green D.E., Warnke L.A., et al. Reactive oxygen species mediate a cellular 'memory' of high glucose stress signalling. Diabetologia 2007, 50:1523-1531.
32. Schisano B., Tripathi G., McGee K., McTernan P.G., Ceriello A. Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells. Diabetologia 2011, 54(May):1219-1226. [Epub 2011 Feb 2].
33. Madsen-Bouterse S.A., Mohammad G., Kanwar M., Kowluru R.A. Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression. Antioxid Redox Signal 2010, 13:797-805.
34. Madsen-Bouterse S.A., Zhong Q., Mohammad G., Ho Y.S., Kowluru R.A. Oxidative damage of mitochondrial DNA in diabetes and its protection by manganese superoxide dismutase. Free Radic Res 2010, 44:313-321.
35. Płoszaj T., Robaszkiewicz A., Witas H. Oxidative damage of mitochondrial DNA: the result or consequence of enhanced generation of reactive oxygen species. Postepy Biochem 2010, 56:139-146.
36. Van Houten B., Woshner V., Santos J.H. Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair (Amst) 2006, 5:145-152.
37. Zong H., Ward M., Stitt A.W. AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep 2011, 11(August):244-252.
38. Yamagishi S., Matsui T. Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Curr Pharm Biotechnol 2011, 12:362-368.
39. Monnier V.M., Bautista O., Kenny D., Sell D.R., Fogarty J., Dahms W., et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes control and complications trial. Diabetes 1999, 48:870-880.
40. Genuth S., Sun W., Cleary P., Sell D.R., Dahms W., Malone J., et al. DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005, 54:3103-3111.
41. Kowluru R.A., Chakrabarti S., Chen S. Re-institution of good metabolic control in diabetic rats and activation of caspase-3 and nuclear transcriptional factor (NF-kappaB) in the retina. Acta Diabetol 2004, 41:194-199.
42. Chan P.S., Kanwar M., Kowluru R.A. Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. J Diabet Complications 2010, 24:55-63.
43. Kowluru R.A., Zhong Q., Kanwar M. Metabolic memory and diabetic retinopathy: role of inflammatory mediators in retinal pericytes. Exp Eye Res 2010, 90:617-623.
44. El-Osta A., Brasacchio D., Yao D., Pocai A., Jones P.L., Roeder R.G., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. Exp Med 2008, 205:2409-2417.
45. Zhong Q., Kowluru R.A. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes 2011, 60:1304-1313.
46. Zhong Q., Kowluru R.A. Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon. J Cell Biochem 2010, 110:1306-1313.
47. Siebel A.L., Fernandez A.Z., El-Osta A. Glycemic memory associated epigenetic changes. Biochem Pharmacol 2010, 80:1853-1859.
48. Berthiaume M., Boufaied N., Moisan A., Gaudreau L. High levels of oxidative stress globally inhibit gene transcription and histone acetylation. DNA Cell Biol 2006, 25:124-134.
49. Mabley J.G., Soriano F.G. Role of nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic vascular dysfunction. Curr Vasc Pharmacol 2005, 3:247-252.
50. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengellér Z., Szabó C., et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003, 112:1049-1057.
51. Yamagishi S., Nakamura K., Matsui T., Noda Y., Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 2008, 14:487-495.
52. Yamagishi S., Nakamura K., Matsui T., Ueda S., Fukami K., Okuda S. Agents that block advanced glycation end product (AGE)-RAGE(receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 2008, 17:983-996.
53. Cooper M.E., El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ Res 2010, 107:1403-1413.
54. Bixler G.V., Vanguilder H.D., Brucklacher R.M., Kimball S.R., Bronson S.K., Freeman W.M. Chronic insulin treatment of diabetes does not fully normalize alterations in the retinal transcriptome. BMC Med Genomics 2011, 4:40.
55. Corgnali M., Piconi L., Ihnat M., Ceriello A. Evaluation of gliclazide ability to attenuate the hyperglycaemic 'memory' induced by high glucose in isolated human endothelial cells. Diabetes Metab Res Rev 2008, 24:301-309.
56. Yamagishi S., Ueda S., Matsui T., Nakamura K., Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des 2008, 14:962-968.
57. Abu El-Asrar A.M., Al-Mezaine H.S. Advances in the treatment of diabetic retinopathy. Discov Med 2010, 9:363-373.
58. Ceriello A., Piconi L., Esposito K., Giugliano D. Telmisartan shows an equivalent effect of vitamin C in further improving endothelial dysfunction after glycemia normalization in type 1 diabetes. Diabetes Care 2007, 30:1694-1698.
59. Keech A.C., Mitchell P., Summanen P.A., O'Day J., Davis T.M., Moffitt M.S., et al. FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370:1687-1697.
60. Chaturvedi N., Porta M., Klein R., Orchard T., Fuller J., Parving H.H., et al. DIRECT Programme Study Group Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008, 372:1394-1402.